Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to new fluorinated quinolones and to their process of preparation.
• R represents an ethyl, fluoroethyl, allyl or benzyl radical optionally substituted by one or more halogens
• R 1 represents hydrogen, an acyl residue derived from an aliphatic, cyclanic or aromatic, mono- or polycarboxylic acid, mono or polyhydroxylated or a residue of alkylcarbonic acid
• R 2 represents oxygen, linked by a semi-polar bond
• n 0 or 1.
• the invention also relates to the salts of quinolone 3-carboxylic acids of general formula I with an inorganic or organic base.
• the quinolones substituted for nitrogen in position 1 will be distinguished more particularly: a) by an ethyl radical
• n 1 1, 2 or 3.
• R 1 is defined as above.
• Z is hydrogen or a halogen atom
• acylated derivatives mention will be made more particularly of those derived from a polycarboxylic acid such as succinic acid, suberic acid, glucaric acid, glutamic acid, l aspartic acid, phthalic acid, terephthalic acid, camphoric acid and similar derivatives, or alternatively a hydroxycarboxylic acid such as gluconic acid, lactobionic acid, glucon ⁇ heptonic acid, glucogluconoheptonic acid .
• a polycarboxylic acid such as succinic acid, suberic acid, glucaric acid, glutamic acid, l aspartic acid, phthalic acid, terephthalic acid, camphoric acid and similar derivatives
• a hydroxycarboxylic acid such as gluconic acid, lactobionic acid, glucon ⁇ heptonic acid, glucogluconoheptonic acid .
• the compounds according to the invention have quite interesting antibacterial properties, in particular with respect to gram (+) germs. They are therefore able to serve as active ingredients in drugs intended to treat external or internal bacterial infections caused by sensitive gram (+) or gram (-) bacteria. To this end, they will be used in the form of pharmaceutical compositions intended for parenteral, oral, rectal, permucosal or topical administration. These pharmaceutical compositions are characterized in that they contain, as active principle, at least one compound of general formula I, or one of its addition salts with an inorganic or organic base, in combination or in mixture with a pharmaceutically acceptable non-toxic excipient or inert carrier.
• nasal drops, ear drops and ophthalmic preparations are the most suitable forms of administration.
• the unit dosage ranges, depending on the compounds, from 100 mg to 500 mg and preferably from 200 to 400 mg of 1-R 1,4-dihydroquinoline 3-carboxylic acid.
• the daily dosage varies depending on the therapeutic indication, the sensitivity of the microbial strains responsible for the infection and the route of administration.
• parenteral, oral or rectal administration between 100 and 1000 mg per day.
• the daily dosage will depend on the percentage of dermal or mucous penetration and the degree of diffusion in the body.
• the invention also comprises a process for obtaining the compounds of general formula I which consists in reacting a 6,7,8-trifluoro 1-R 1,4-dihydroquinoline 4-one 3-carboxylic acid of formula II
• R has the same meanings as above which can be subjected to acylation using a functional derivative of carboxylic acid
• the IR spectrum conforms to the structure.
• the product is soluble in 1N sodium hydroxide while warming.
• the minimum inhibitory concentrations were measured by a microdilution technique (*) in liquid medium (MuellerHinton broth) in a volume of 100 ⁇ l and for a concentration range ranging from 128 to 0.06 mg / l, prepared from a stock solution of antibiotic titrating 512 mg / l.
• the preparation of these stock solutions carried out varied according to the molecules as a function of the solubility criteria.
• the inoculation is done by adding to each cup 10 ⁇ l of a dilution in physiological water of a broth of 18 hours in broth of the brain, such that each cup contains about 10 bacteria / ml.
• the minimum inhibitory concentration is read as the first concentration of non-culture-giving antibiotic, macroscopically visible after 18 hours of incubation at 37 °.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Pharmacology & Pharmacy (AREA)
• Oncology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Examining Or Testing Airtightness (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9410967

Family Applications (1)

Country Status (6)

Families Citing this family (3)

Family Cites Families (7)

• 1991
  • 1991-03-19 FR FR9103421A patent/FR2674247B1/fr not_active Expired - Fee Related
• 1992
  • 1992-03-18 EP EP92908914A patent/EP0530355A1/de not_active Withdrawn
  • 1992-03-18 WO PCT/FR1992/000243 patent/WO1992016521A1/fr not_active Ceased
  • 1992-03-18 JP JP4508023A patent/JPH06500338A/ja active Pending
  • 1992-03-18 FI FI925240A patent/FI925240L/fi not_active Application Discontinuation
  • 1992-03-18 AU AU16459/92A patent/AU1645992A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events